Core Insights - The study of acoramidis in the ATTRibute-CM trial indicates that early and sustained increases in serum transthyretin (TTR) levels are associated with improved survival outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [1][2][5] - Acoramidis, a near-complete TTR stabilizer, has shown significant clinical benefits, including reductions in all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) [1][6][12] Group 1: Clinical Findings - A 5-mg/dL increase in serum TTR level within 28 days of treatment initiation correlates with a relative risk reduction of mortality of up to 31.6% through Month 30 [1][5] - The ATTRibute-CM study is the first to demonstrate a direct link between increased serum TTR and survival in ATTR-CM patients [1][2] - Acoramidis treatment resulted in a mean increase of 9.1 mg/dL in serum TTR levels within 28 days, which was sustained throughout the 30-month treatment period [5][6] Group 2: Statistical Outcomes - The study reported a 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 [4] - A 50% reduction in the cumulative frequency of CVH events was observed relative to placebo at Month 30 [4] - The analysis showed that the early increase in serum TTR levels was associated with reduced ACM, independent of baseline risk factors [5][6][12] Group 3: Regulatory Approvals - Acoramidis is approved as Attruby™ by the U.S. FDA and as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency [1][7] Group 4: Company Overview - BridgeBio Pharma, Inc. focuses on developing transformative medicines for genetic diseases and has a pipeline that includes advanced clinical trials [10]

Company Information - Spineway is engaged in the design, manufacture, and marketing of innovative implants and surgical instruments for treating severe spinal disorders [7] - The company has an international network of over 50 independent distributors, with more than 70% of its revenue generated from exports [7] Upcoming Events - A Combined General Meeting is scheduled for June 4, 2025, at 2:00 p.m. at the Group's headquarters in Ecully [3] - The notice of the meeting, including the agenda and resolutions, was published on April 30, 2025 [4] - The next financial report, detailing H1 2025 revenue, is expected on July 30, 2025 [5] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), which may attract certain investors [6] - All preparatory documents for the General Meeting can be accessed on the company's website under "Investors/Regulated Information" [5]

Core Insights - Kymera Therapeutics announced promising preclinical data for KT-621, an oral STAT6 degrader, showing comparable or superior efficacy to dupilumab in chronic asthma models [1][3] - The company has completed a Phase 1 trial for KT-621 and plans to report data in June 2025, with ongoing trials for atopic dermatitis and upcoming Phase 2b trials for asthma and atopic dermatitis [4][1] Group 1: KT-621 Development - KT-621 is the first STAT6 targeted medicine to enter clinical development, demonstrating potential as a once-daily oral treatment for asthma and other Th2 allergic diseases [1][6] - Preclinical data indicate that KT-621 can prevent disease progression and reverse established disease in asthma models, outperforming dupilumab in certain metrics [3][1] - The company plans to initiate two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively [4][1] Group 2: Clinical Trials and Data - The Phase 1 healthy volunteer trial for KT-621 has been completed, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics [4][1] - Data from the ongoing KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is expected in the fourth quarter of 2025 [4][1] - A webcast is scheduled for June 2025 to disclose comprehensive data from the Phase 1 trials, including safety and biomarker results [4][1] Group 3: Company Vision and Market Potential - Kymera Therapeutics aims to expand patient access to oral systemic therapies for immuno-inflammatory diseases, addressing a significant unmet need in the market [3][6] - The company emphasizes the convenience of KT-621 as an oral medication, which could reach broader patient populations compared to injectable biologics [6][3] - KT-621 has the potential to transform treatment paradigms for over 130 million patients globally suffering from Th2 diseases [6][1]

PRESS RELEASE Regulated Information NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED ( ...

Group 1 - Sodexo conducted a share buyback program from May 12 to May 14, 2025, purchasing a total of 100,000 shares at an average price of €56.5051 [1] - The share buyback was authorized by the Shareholders' Meeting held on December 17, 2024, and was aimed at fulfilling obligations related to free shares award plans [1] - The transactions included various trading dates and volumes, with the highest purchase price recorded at €57.3105 on May 13, 2025 [1] Group 2 - Sodexo, founded in 1966, is a global leader in sustainable food and facilities management services, emphasizing a responsible business model [2] - The company operates in 45 countries and serves 80 million consumers daily, with consolidated revenues of €23.8 billion for fiscal 2024 [3] - As of April 3, 2025, Sodexo's market capitalization was €8.5 billion, and it is recognized as the number one France-based private employer worldwide [3]

RELEASE DISCLOSURE OF TRADING IN OWN SHARES FROM MAY 12 TO MAY 13, 2025 In accordance with the authorization granted by the Shareholders’ Meeting in order to trade in own shares and pursuant to applicable law on share repurchases, Rexel declares the following purchases of its own shares from May 12 to May 13, 2025: Name of the issuerIdentity code of the issuer (Legal Entity Identifier)Day of transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted avera ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect,” “our” or “we”) announced today that it will redeem all outstanding 3.706% Notes due 2026 (the “Notes”) at a price of 100% of the principal amount of the Notes to be redeemed, plus accrued but unpaid interest, to but excluding the Redemption Date (the “Redemption Price”). The redemption date will be June 18, 2025 (the “Redemption Date”). The Notes are held through The Depository Trust Company and will be redee ...

Expanded lineup includes new ROG Strix, Zephyrus, and ASUS TUF Gaming laptops powered by NVIDIA GeForce RTX 5060 laptop GPUs — with configurations available today TORONTO, May 19, 2025 (GLOBE NEWSWIRE) -- ASUS Republic of Gamers (ROG) has announced the arrival of new NVIDIA GeForce RTX 5060 Laptop GPUs-equipped configurations across its acclaimed ROG Strix, Zephyrus, and TUF Gaming laptop families — now available in Canada. This expanded lineup features the latest from NVIDIA, including cutting-edge graphi ...

PRESS RELEASE Arcueil, May 19, 2025 2025 first-half results Double-digit revenue growth, doubling of adjusted EBITDA, solid cash generationAnnual targets confirmed Results on March 31, 2025, first half of the financial year ending September 30, 2025 Revenue of €1,213.3 million, organic growth of +10% compared to the first half of 2024Customer satisfaction remains very high, with an NPS1 of 72, among the best in the industry and supported by continued team engagement, illustrated by a strong eNPS2 of 55+10% ...

Core Viewpoint - Renault S.A. has announced a share buyback program from May 9 to May 16, 2025, with a maximum of 1,500,000 shares to be repurchased to fulfill obligations related to performance shares and long-term incentive plans for the Group's CEO and senior managers [1]. Group 1: Share Buyback Details - The share buyback program is conducted under a mandate given to an investment services provider [1]. - The total number of shares targeted for repurchase is 1,500,000 [6]. - The average price of shares repurchased during this period is 48.5531 [6]. Group 2: Daily Transaction Summary - On May 9, 2025, a total of 194,401 shares were purchased at an average price of 47.3934 on XPAR [2]. - On May 12, 2025, 186,600 shares were bought at an average price of 48.6420 on XPAR [2]. - On May 16, 2025, 152,203 shares were acquired at an average price of 49.2119 on XPAR [3]. Group 3: Additional Information - Detailed information regarding the share buyback program can be found on Renault Group's official website under the "Investors / Regulated Information / Share buyback program" section [4].